Overall verdict
Neutral
5.1/10
1-year performance
+81.47%
Score breakdown
Up 81.5% over 1 year, 95% of the 52-week range.
Strongest: Financial strength 7.8/10. Weakest: Growth 2.0/10.
26 analysts, target +0.1% vs the price.
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination ; individual Medicare stand-alone prescription drug products (PDP) ; group Medicare advantage and Medicare stand-alone PDP ;
Medicare supplements ; specialty and ancillary insurance comprising dental, vision, life and disability ; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands ;
a management services organization ; CenterWell Home Health, a home health provider ; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
James Rechtin
Founded
1961
Employees
67 060
Revenue / employee
1.9M USD
Next earnings
February 10, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.73%
- FMR LLC1.62%
- Bank of New York Mellon Corp0.51%
- Rest of the register95.14%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
456.50 USD
52-week low
163.11 USD
1-year performance
81.47%
Rising
Year-to-date performance
72.73%
Rising
Drawdown
-3.10%
Near its high
Position in the 52-week range
95% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Humana | $312,708 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.4 times as much as the world ETF.
- Worst fall:-70 % between January 2008 and February 2009. $10,000 placed at the top fell to $2,977. The world ETF, at worst: -53 %. Back to its high in 27 months.
Humana earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Humana: $312,708
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 359.94 USD - 445.09 USD (3 methods agree)
The price implies growth of 2.81% per year; the company grows at -10.00%.
Net margin 0.8%, ROIC 4.1%, ROE 6.7%.
Net margin
0.81%
Low
Sector 1.63%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
6.67%
Low
Sector 10.99%|S&P 17.06%
Return on invested capital (ROIC)
4.05%
Low
Free cash flow margin (FCF)
2.04%
Low
Profit-to-cash conversion (FCF conversion)
2.52x
High
Margin stability
1.3 pts
Very steady
Revenue to net income
Growth
2.0/10Revenue up 26.1% over 1 year, 10.9% a year over 5, EPS -17.2% a year over 5.
Revenue (trailing 12 months)
154Md USD
Revenue growth (1y)
26.05%
Hyper-growth
Revenue growth (3y)
39.59%
Solid
EPS growth (1y)
-17.67%
Declining
EPS CAGR (5y)
-17.23%
Declining
EPS revisions (3 months)
3.99%
Revised up
Valuation
2.6/10P/E 43.1x, forward P/E 52.5x, EV/EBITDA 15.4x. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
43.1x
Expensive
Sector 28.8x|S&P 23.6x
Forward P/E
52.5x
Very expensive
EV / EBITDA
15.4x
Fair
Sector 18.5x|S&P 15.5x
PEG
—
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
420.70 USD
Fairly priced
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
53.1Md USD
Financial strength
7.8/10Cash covers 55.5% of the debt, net debt/EBITDA -2.2x.
Net debt / EBITDA
-2.2x
Net cash
Gearing (net debt / equity)
29.48%
Very solid
Cash
6.9Md USD
Cash / market cap
13.05%
Solid
Cash / total debt
55.46%
Solid
Interest coverage
3.2x
Tight
Net debt
5.6Md USD
Equity
18.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 438.06 USD
- MM20420.60
- MM50405.92
- MM200313.64
- RSI 1460.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+5.33%
200-day average slope, 3 months
+16.53%
50-day average slope, 1 month
+4.24%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.12 % per day
Volatility change
-14.57%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 8.42 (8) | 9.45 (22) | 162 900 (15) | 2 885 (12) | 988 (4) |
| 2027 | 17.46 (9) | 17.90 (25) | 171 937 (21) | 4 141 (13) | 130 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.2 | 7.5 | 2.7Md USD | 33.5x | 6.8 % | 8.9 % | 17.8 % | -3.1x | 6.7 % | 53.4 % | ||
| 2 | HQY | 7.0 | 6.8 | 8.5Md USD | 37.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 5.7 % | 3.4 % | ||
| 3 | ELV | 6.8 | 6.7 | 92.8Md USD | 18.3x | 2.5 % | 1.4 % | 6.8 % | 3.0x | 7.0 % | 40.0 % | ||
| 4 | UNH | 6.8 | 6.7 | 361Md USD | 23.0x | 3.5 % | -0.4 % | 9.5 % | 1.8x | 6.3 % | 24.6 % | ||
| 5 | SAUD3 | 6.4 | 5.9 | 8.4Md USD | 16.8x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.5 % | 36.5 % | ||
| 6 | CNC | 5.8 | 5.8 | 34.9Md USD | 24.2x | 0.7 % | 1.9 % | 3.8 % | -1.4x | 11.3 % | 102.9 % | ||
| 7 | HUM | 5.1 | 3.5 | 53.1Md USD | 43.1x | 0.8 % | 26.1 % | 4.1 % | -2.2x | 5.9 % | 81.5 % | ||
| 8 | MOH | 4.7 | 2.8 | 10.9Md USD | Not meaningful (loss) | -0.1 % | -3.4 % | -0.6 % | -22.1x | 2.2 % | 47.1 % | ||
| 9 | CLOV | 4.3 | 1.9 | 2.6Md USD | 263.0x | 0.5 % | 52.9 % | — | — | — | 91.2 % |
